Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a LookThe Motley Fool • 11/05/25
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032PRNewsWire • 11/05/25
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/25
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/04/25
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTSPRNewsWire • 11/03/25
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/27/25
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?Zacks Investment Research • 10/23/25
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040sPRNewsWire • 10/01/25
Powell Warns of Valuation Risks: 5 High Earnings Yield Value PicksZacks Investment Research • 09/24/25
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should KnowZacks Investment Research • 09/19/25
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate CutsZacks Investment Research • 09/09/25
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust ReturnsZacks Investment Research • 09/05/25
Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks TranscriptSeeking Alpha • 09/04/25